Remove 2017 Remove Company Focus Remove Service
article thumbnail

Combating Cybersecurity Threats With Globalization

Zinnov

Companies are looking to invest in the APT (Advance Persistent Threat), IAM (Identity and Access Management), and Encryption segments to develop solutions to prevent breaches arising from emails, Cloud platforms and services, endpoints, and networks. They have a higher percentage of low-cost globalization as well as insourcing.

article thumbnail

Their Last Bite Of The Apple: Why West Coast Port Workers Are Fighting For Less Automation And More Pay

SIG Speaks

You have a tire with a slow leak and must repeatedly pull into a service station to fill it to the proper inflation rate. In California, the contract that just ended on July 1 st , 2022, was part of an extension of a previous agreement between the union and management in 2017. I like to think of it as the slow-leak tire syndrome.

professionals

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Ultimate Guide To Outsourcing – What You Need To Know

Magellan Solutions

And sometimes, temporary employees don’t always live up to your company’s expectations. So by partnering with an outsourcing company, it lets your company focus human resources on where it needs the most. Outsourcing can help your business shift its focus from peripheral activities to work that serves the customer.

article thumbnail

Kofax: Accelerating the Journey from ‘Capture’ to ‘Hyper Intelligent Automation’

Zinnov

In the first couple of decades of its existence, Kofax, which was founded as a hardware tech company, evolved into a software platform provider. Initially, the company focused on building capabilities in the Business Process Management (BPM) space and increasing its IDP prowess.

article thumbnail

Six innovation strategies for Life Science organizations in 2023

IBM Services

The US Food & Drug Administration (FDA) approved the first gene therapy in the United States in 2017. Since then, companies such as Insilico Medicine, Evotec and Schrödinger have announced phase I trials. Since then, more than 20 cell and gene therapy products have been approved.